Search
Invitrogen
Human VEGFR3 (Flt-4) Fc Chimera Recombinant Protein
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Additional Information:
{{banner.description}}
Product Details
RP-88180
Applications
Tested Dilution
Publications
Product Specifications
Species
Human
Expression System
HEK293 cells
Amino acid sequence
Human VEGFR3, amino acids Met1-Ile776 (Accession # NP_002011.2) with a C-terminal human IgG1 Fc region
Tag
Fc-tag
Molecular weight
111.3 kDa
Class
Recombinant
Type
Protein
Purity
>97% as determined by SDS-PAGE.
Endotoxin concentration
<1.0 EU/µg
Activity
Measured by its binding ability in a functional ELISA. 1. Immobilized recombinant human VEGFR3 at 5 µg/ml (100 µL/well) can bind recombinant human VEGF-D at a linear range of 62.5-2000 ng/mL. 2. Immobilized recombinant human VEGF-C at 10 µg/ml (100 µL/well) can bind recombinant human VEGFR3 at a linear range of 0.64-80 ng/mL. 3. Scatchard analysis showed the affinity constant (Kd) of recombinant human VEGF-C bound to recombinant human VEGFR3 was 1.4 nM.
Conjugate
Form
Lyophilized
Amount
1 mg
Purification
purified
Storage buffer
PBS, pH 7.4, with 0.01% mannitol, 5-8% trehalose, 0.01% Tween 80
Contains
no preservative
Storage conditions
-20°C, Avoid Freeze/Thaw Cycles
Shipping conditions
Wet ice
Product Specific Information
It is recommended that the protein be aliquoted for optimal storage.
It is recommended that sterile water (900 µL) be added to the vial to prepare a stock solution of 1.11 mg/mL.
Concentration is measured by UV.
Target Information
Vascular endothelial growth factor is a key regulator of blood vessel development in embryos and angiogenesis in adult tissues. Unlike VEGF, the related VEGFC stimulates the growth of lymphatic vessels through its specificl ymphatic endothelial receptor VEGFR-3. In 1998, Dumont showed that targeted inactivation of the VEGFR-3 gene in mice resulted in defective blood vessel development in early embryos. Vasculogenesis and angiogenesis occurred, but large vessels became abnormally organized with defective lumens, leading to fluid accumulation in the pericardial cavity and cardiovascular failure at embryonic day 9.5. Thus, VEGFR3 has an essential role in the development of theembryonic cardiovascular system before the emergence of the lymphatic vessels.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Bioinformatics
Protein Aliases: alternatively spliced; Feline McDonough Sarcoma (FMS)-like tyrosine kinase 4; FLT-4; fms related tyrosine kinase 4; Fms-like tyrosine kinase 4; primary congenital lymphedema; soluble VEGFR 3; sVEGFR 3; Tyrosine-protein kinase receptor FLT4; unnamed protein product; Vascular endothelial growth factor receptor 3; VEGF R3; VEGF receptor-3; VEGFR-3
Gene Aliases: CHTD7; FLT-4; FLT4; FLT41; LMPH1A; LMPHM1; PCL; VEGFR-3; VEGFR3
UniProt ID: (Human) A8K6L4
Entrez Gene ID: (Human) 2324
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support